Sponsored By
Norbert Sparrow

September 7, 2016

2 Min Read
Medical materials company raises record funds to develop devices with bacteria-phobic coating

Medical materials company Camstent (Sharnbrook, UK) announced  on Sept. 1 that it has closed its latest funding round, raising a record £850,000 ($1.1 million) from a combination of existing and new investors. The company reports that enormous interest in its patented bacteria-phobic polymer coatings led to an extension of the initial investment target of £300,000, which it nearly tripled during the latest funding round.

Camstent’s coatings reportedly reduce the incidence of hospital-acquired infections (HAIs) by changing the physical properties of surfaces to make them inhospitable to bacteria, writes the Cambridge Network, an organization that brings together members of industry and academe in Cambridge’s high-tech cluster. Studies have shown that the technology developed by Camstent lasts longer and is more effective than market-leading alternatives, according to Cambridge Network.

On any given day, about one in 25 hospital patients has at least one HAI, according to the Centers for Disease Control and Prevention. HAIs cause thousands of deaths globally and add significant cost to healthcare budgets.

The funding will be used to accelerate the company’s development, beginning with gaining CE mark approval for Camstent’s first product, the Foley Catheter, says the company in a news release. CE mark approval, which allows the product to be sold throughout the European Union and in other countries that recognize the marking, is expected in Q4 2016. Once approved, the catheter will be shipped for trials and first volume sales from Camstent’s recently announced UK manufacturing facility.

As well as bringing the Camstent Foley Catheter to market, the new funding will be used to develop clinical and marketing partnerships and to enable the company to expand into additional medical products, such as tracheal tubes, vagina pessaries and ureteral stents, based on its intellectual property and existing facilities.

The coatings use proprietary polymers formed from two methacrylate components, explains the company on its website. One coating prevents bacteria from maintaining contact with the device surface, while the other imparts flexibility. No anti-bacterial or antibiotic agents are used in the formulation, and the coatings are devoid of toxins, which are used in some competing products to repel and kill bacteria. The absence of anti-bacterial agents means that the Camstent catheter will not contribute to bacterial resistance and help combat the difficulty of treating HAIs caused by antibiotic-resistant organisms.

About the Author(s)

Norbert Sparrow

Editor in chief of PlasticsToday since 2015, Norbert Sparrow has more than 30 years of editorial experience in business-to-business media. He studied journalism at the Centre Universitaire d'Etudes du Journalisme in Strasbourg, France, where he earned a master's degree.

www.linkedin.com/in/norbertsparrow

Sign up for the PlasticsToday NewsFeed newsletter.

You May Also Like